Lincoln Pharma reports Best-Ever Results in a Financial Year; Reports Highest Revenue, EBIDTA, Net Profit in FY22

Company recommends 15% dividend, Rs. 1.50 per share for FY 22 

FY22 Results Highlights:– (Standalone) ·         Net Profit Reports Y-o-Y growth of 11.42% to Rs. 69.36 crore; ·         Net Revenues from operations reports Y-o-Y growth of 11.63% to Rs. 472.08 crore; ·         EBITDA reports Y-o-Y growth of 13.67% to Rs. 105.47 crore. Business Highlights:- ·         FOB Value of exports for FY22 reports Rs. 266.18 crore; ·         Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore; ·         CRISIL has upgraded its ratings on the company’s bank facilities to ‘CRISIL A/Stable/CRISIL A1’; ·         Company achieved strong liquidity position supported by healthy cash accruals and become Net Debt free.

 

Financial Highlights (Standalone)                 (Amount in Cr except EPS)

Particulars	FY22	FY21	Y-O-Y
Net Revenue from Operations	472.08	422.91	11.63%
EBITDA	105.47	92.78	13.67%
Profit before Tax	95.93	83.67	14.65%
Net Profit	69.36	62.25	11.42%
E.P.S (Rs.)	34.63	31.08	11.42%

Ahmedabad, May 19, 2022: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported its Best-ever results in a financial year with highest – Revenue, EBITDA and Net Profit for the FY ended March 2022. Company has recommended a dividend of 15%, Rs. 1.50 per share on the face value of Rs. 10 per share for the FY 2021-22.

Company reported net profit of Rs. 69.36 crore for FY22 as against net profit of Rs. 62.25 crore in the corresponding period last year, growth of 11.42%. Net revenue from operations for FY22 was reported at Rs. 472.08 crore, higher by 11.63% over previous fiscal’s same period revenue of Rs. 422.91 crore. Company reported EBITDA of Rs. 105.47 crore in FY22, rise of 13.67% as compared to EBITDA of Rs. 92.78 crore in FY21. EPS for FY22 was reported at Rs. 34.63 per share.

Commenting on the results and performance, Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited, said, “We feel proud to inform all our stakeholders that the company is progressing well on its long-term growth roadmap. Company has reported excellent numbers for FY 2022 with highest Revenue, EBITDA and Net Profit reported on a yearly basis. With a robust performance, the company has recommended a dividend of Rs. 1.50 per share. Company’s expansion plans for Cephalosporin products and foray in EU and Australian markets are also progressing well. Company is growing strength to strength, delivering robust operational and

financial performance maintaining healthy growth in revenue, margins and profitability. We expect the growth momentum to continue and expect to get further boost in coming years.”

CRISIL Ratings has upgraded its ratings on the bank facilities of Lincoln Pharmaceuticals Ltd to ‘CRISIL A/Stable/CRISIL A1’ from CRISIL A-/Positive/CRISIL A2+. CRISIL report further states that, “The rating upgrade reflects the Lincoln group’s improved business profile and the continued consolidation in the financial risk profile. Over the medium term, the group is expected to maintain its growth trajectory and healthy margin. This shall be supported by addition of Cephalosporin which has potential to add around 30% to the topline over next three fiscals. Further, the group’s European market foray shall provide additional fillip to the business profile.” 

Financial Overview – Lincoln Pharmaceuticals FY 12 to FY22 Year Revenue EBITDA Net Profit EPS ROCE FY 22 472.08 105.47 69.36 34.63 21.93% FY 12 175.5 16.9 5.12 3.14 10% 10 Yrs CAGR 10.40% 20.09% 29.77% 27.13% 8.17% During the last 10 years from FY12 to FY22, Lincoln Pharmaceuticals Ltd has delivered a robust 29.77% plus CAGR in Net profits, 20.09% in EBITDA and 10.40% in Revenue. The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, free cash/liquid investments, no term debt and healthy return ratios. Rating agency ICRA too has reaffirmed the company’s long-term and short-term bank facilities to A and A1 respectively.

Update on Cephalosporin Expansion – In September 2021, company acquired a plant in Mehsana, Gujarat to launch Cephalosporin products. Capital investment using internal source of fund for acquisition of cephalosporin plant (including capacity expansion) for Rs. 30 crore. The plant is expected to contribute sales of around Rs. 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.

Export business of the company has shown strong growth over the years. It currently exports to 60 plus countries including East & West Africa, Central & Latin America and Southeast Asia. TGA – Australia and EU GMP approvals will strengthen the company’s presence and expand its network to 90 plus countries. FOB Value of Exports for FY22 reports of Rs. 266.18 crore. 

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP, TGA – Australia and ISO-9001: 2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, ant-diabetic, anti-malaria among others. To complement the company’s strong presence in the acute segment, the company is also building a portfolio in lifestyle and chronic segments especially dermatology, gastro and pain management. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

Corporate Comm India (CCI Newswire)